These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
146 related items for PubMed ID: 2880862
1. Differences in the opioid control of luteinizing hormone secretion between pathological and iatrogenic hyperprolactinemic states. Petraglia F, De Leo V, Nappi C, Facchinetti F, Montemagno U, Brambilla F, Genazzani AR. J Clin Endocrinol Metab; 1987 Mar; 64(3):508-12. PubMed ID: 2880862 [Abstract] [Full Text] [Related]
2. Parallelism in the luteinizing hormone responses to opioid and dopamine antagonists in hyperprolactinemic women with pituitary microadenoma. Seki K, Kato K, Shima K. J Clin Endocrinol Metab; 1986 Nov; 63(5):1225-8. PubMed ID: 3760121 [Abstract] [Full Text] [Related]
3. Naloxone increases the frequency of pulsatile luteinizing hormone secretion in women with hyperprolactinemia. Cook CB, Nippoldt TB, Kletter GB, Kelch RP, Marshall JC. J Clin Endocrinol Metab; 1991 Nov; 73(5):1099-105. PubMed ID: 1939525 [Abstract] [Full Text] [Related]
4. Evidence for an increased opioid inhibition of luteinizing hormone secretion in hyperprolactinemic patients with pituitary microadenoma. Quigley ME, Sheehan KL, Casper RF, Yen SS. J Clin Endocrinol Metab; 1980 Mar; 50(3):427-30. PubMed ID: 7358828 [Abstract] [Full Text] [Related]
5. Evidence for increased dopaminergic and opioid activity in patients with hypothalamic hypogonadotropic amenorrhea. Quigley ME, Sheehan KL, Casper RF, Yen SS. J Clin Endocrinol Metab; 1980 May; 50(5):949-54. PubMed ID: 6246138 [Abstract] [Full Text] [Related]
6. Effect of chronic opioid antagonism on the hypothalamic-pituitary-ovarian axis in hyperprolactinemic women. Matera C, Freda PU, Ferin M, Wardlaw SL. J Clin Endocrinol Metab; 1995 Feb; 80(2):540-5. PubMed ID: 7852517 [Abstract] [Full Text] [Related]
7. Catecholamines and pituitary function. VII: Effects of acute and chronic dopamine-receptor blockade on pituitary response to TRH-GNRH in normal women and in patients with hyperprolactinemic amenorrhea. Giammartino C, Ambrosi F, Pelicci G, Pagliacci MC, Fedeli L, Nicoletti I. Horm Metab Res; 1988 Jan; 20(1):44-8. PubMed ID: 3131222 [Abstract] [Full Text] [Related]
8. Catecholamines and pituitary-function. V. Effect of low-dose dopamine infusion on basal and gonadotropin-releasing hormone stimulated gonadotropin release in normal cycling women and patients with hyperprolactinemic amenorrhea. Nicoletti I, Ambrosi F, Giammartino C, Fedeli L, Mannarelli C, Filipponi P. Horm Metab Res; 1986 Jul; 18(7):479-84. PubMed ID: 3091473 [Abstract] [Full Text] [Related]
9. Hyperprolactinemia decreases the luteinizing hormone-releasing hormone concentration in pituitary portal plasma: a possible role for beta-endorphin as a mediator. Sarkar DK, Yen SS. Endocrinology; 1985 May; 116(5):2080-4. PubMed ID: 3157564 [Abstract] [Full Text] [Related]
10. The role of endogenous opiates in the mechanism of inhibited luteinizing hormone (LH) secretion in women with anorexia nervosa: the effect of naloxone on LH, follicle-stimulating hormone, prolactin, and beta-endorphin secretion. Baranowska B, Rozbicka G, Jeske W, Abdel-Fattah MH. J Clin Endocrinol Metab; 1984 Sep; 59(3):412-6. PubMed ID: 6086696 [Abstract] [Full Text] [Related]
11. A possible role of endogenous opioids in the control of prolactin and luteinizing-hormone secretion in the human. Veldhuis JD, Worgul TJ, Monsaert R, Hammond JM. J Endocrinol Invest; 1981 Sep; 4(1):31-6. PubMed ID: 7240669 [Abstract] [Full Text] [Related]
12. The disappearance of opioidergic regulation of gonadotropin secretion in postmenopausal women. Reid RL, Quigley ME, Yen SS. J Clin Endocrinol Metab; 1983 Dec; 57(6):1107-10. PubMed ID: 6313728 [Abstract] [Full Text] [Related]
13. Constancy of opioid control of luteinizing hormone in different pathophysiological states. Lightman SL, Jacobs HS, Maguire AK, McGarrick G, Jeffcoate SL. J Clin Endocrinol Metab; 1981 Jun; 52(6):1260-3. PubMed ID: 6785301 [Abstract] [Full Text] [Related]
15. The effect of naloxone and metoclopramide on the secretion of luteinizing hormone in a hyperprolactinemic hypogonadotropic postmenopausal woman. Verhelst J, Beckers A, Abs R. Fertil Steril; 1995 Nov; 64(5):969-71. PubMed ID: 7589643 [Abstract] [Full Text] [Related]
16. The effect of hyperprolactinemia produced by transplantable pituitary MtTW15 tumor cells in male rats on hypothalamic luteinizing hormone-releasing hormone release in vitro: effects of naloxone and K+. Kalra PS, Kalra SP. Endocrinology; 1987 Jul; 121(1):310-5. PubMed ID: 3297642 [Abstract] [Full Text] [Related]
17. Altered neuroendocrine regulation of luteinizing hormone secretion in postmenopausal women with Parkinson's disease. Cagnacci A, Melis GB, Soldani R, Bonuccelli U, Piccini P, Napolitano A, Muratorio A, Fioretti P. Neuroendocrinology; 1991 Jun; 53(6):549-55. PubMed ID: 1678880 [Abstract] [Full Text] [Related]
18. Exaggerated circadian variation in basal thyrotropin (TSH) and in the dopaminergic inhibition of TSH release in pathological hyperprolactinemia: evidence against a hypothalamic dopaminergic defect. Rodriguez-Arnao MD, Peters JR, Foord SM, Dieguez C, Edwards C, Gomez-Pan A, Hall R, Newcombe RG, Scanlon MF. J Clin Endocrinol Metab; 1983 Nov; 57(5):975-80. PubMed ID: 6619271 [Abstract] [Full Text] [Related]